ZA914165B - Pharmacologically active CNS compounds. - Google Patents
Pharmacologically active CNS compounds.Info
- Publication number
- ZA914165B ZA914165B ZA914165A ZA914165A ZA914165B ZA 914165 B ZA914165 B ZA 914165B ZA 914165 A ZA914165 A ZA 914165A ZA 914165 A ZA914165 A ZA 914165A ZA 914165 B ZA914165 B ZA 914165B
- Authority
- ZA
- South Africa
- Prior art keywords
- hydrogen
- halo
- alkyl
- compounds
- pharmacologically active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Paper (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909012316A GB9012316D0 (en) | 1990-06-01 | 1990-06-01 | Pharmacologically active cns compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA914165B true ZA914165B (en) | 1993-03-01 |
Family
ID=10676964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA914165A ZA914165B (en) | 1990-06-01 | 1991-05-30 | Pharmacologically active CNS compounds. |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP0679645A1 (de) |
JP (1) | JPH06340634A (de) |
KR (1) | KR920000733A (de) |
AT (1) | ATE141263T1 (de) |
AU (2) | AU652753B2 (de) |
CA (1) | CA2043640A1 (de) |
CZ (1) | CZ281070B6 (de) |
DE (1) | DE69121317T2 (de) |
DK (1) | DK0459819T3 (de) |
ES (1) | ES2093078T3 (de) |
FI (1) | FI912623A (de) |
GB (1) | GB9012316D0 (de) |
GR (1) | GR3021237T3 (de) |
HU (2) | HUT58707A (de) |
IE (1) | IE911861A1 (de) |
IL (2) | IL113599A (de) |
MY (2) | MY109958A (de) |
NO (1) | NO180375C (de) |
NZ (3) | NZ272001A (de) |
PL (2) | PL170373B1 (de) |
PT (1) | PT97827B (de) |
RU (1) | RU2091374C1 (de) |
SK (1) | SK278444B6 (de) |
TW (1) | TW224460B (de) |
ZA (1) | ZA914165B (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI895821A0 (fi) * | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
PL169106B1 (pl) * | 1991-01-30 | 1996-06-28 | Wellcome Found | Sposób wytwarzania dyspergowalnej w wodzie tabletki PL PL PL PL PL PL PL |
US5629016A (en) * | 1991-01-30 | 1997-05-13 | Glaxo Wellcome Inc. | Water-dispersible tablets |
GB9215908D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Water dispersible tablets |
GB9226377D0 (en) * | 1992-12-18 | 1993-02-10 | Babbedge Rachel C | Pharmaceutical compositions |
AU5704594A (en) * | 1992-12-18 | 1994-07-19 | Wellcome Foundation Limited, The | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
GB9319341D0 (en) * | 1993-09-17 | 1993-11-03 | Wellcome Found | Novel process |
FR2741879A1 (fr) * | 1995-12-05 | 1997-06-06 | Esteve Labor Dr | Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
CN102584799A (zh) | 1999-09-16 | 2012-07-18 | 田边三菱制药株式会社 | 含氮的6-员芳香环化合物 |
CN1657523A (zh) | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
JP5154728B2 (ja) * | 2000-07-24 | 2013-02-27 | クレニツキー・ファーマシューティカルズ,インコーポレイテッド | 神経栄養活性を有する置換5−アルキニルピリミジン |
CN1503797A (zh) | 2001-02-26 | 2004-06-09 | 田边制药株式会社 | 吡啶并嘧啶或二氮杂萘衍生物 |
BR0307429A (pt) * | 2002-02-05 | 2004-12-28 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3 |
TW200637556A (en) * | 2005-01-31 | 2006-11-01 | Basf Ag | Substituted 5-phenyl pyrimidines I in therapy |
CN103110635A (zh) | 2005-07-04 | 2013-05-22 | 海波因特制药有限责任公司 | 组胺h3受体拮抗剂 |
EP2038256A1 (de) | 2006-05-23 | 2009-03-25 | TransTech Pharma, Inc | 6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridin und seine verwendung als arzneimittel |
EA016026B1 (ru) | 2006-05-29 | 2012-01-30 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | 3-(1,3-бензодиоксол-5-ил)-6-(4-циклопропилпиперазин-1-ил)пиридазин, его соли и сольваты и его применение в качестве антагониста н3 рецептора гистамина |
EP2014656A3 (de) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | Neue heterocyclische H3-Antagonisten |
MX354412B (es) | 2011-06-10 | 2018-03-05 | Merck Patent Gmbh | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
EP3094627B1 (de) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-pyridazin-(triazin-3-yl-piper(-azin)/idin/pyrolidin-derivate und zusammensetzungen daraus zur hemmung der aktivität von shp2 |
PL3468972T3 (pl) | 2016-06-14 | 2020-11-16 | Novartis Ag | Związki i kompozycje do hamowania aktywności shp2 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE518622A (de) * | ||||
FI895821A0 (fi) * | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
US5136080A (en) * | 1989-12-04 | 1992-08-04 | Burroughs Wellcome Co. | Nitrile compounds |
-
1990
- 1990-06-01 GB GB909012316A patent/GB9012316D0/en active Pending
-
1991
- 1991-05-30 ZA ZA914165A patent/ZA914165B/xx unknown
- 1991-05-31 MY MYPI91000962A patent/MY109958A/en unknown
- 1991-05-31 NZ NZ272001A patent/NZ272001A/en unknown
- 1991-05-31 CZ CS911643A patent/CZ281070B6/cs unknown
- 1991-05-31 KR KR1019910009010A patent/KR920000733A/ko not_active Application Discontinuation
- 1991-05-31 PT PT97827A patent/PT97827B/pt not_active IP Right Cessation
- 1991-05-31 MY MYPI95001459A patent/MY136248A/en unknown
- 1991-05-31 CA CA002043640A patent/CA2043640A1/en not_active Abandoned
- 1991-05-31 EP EP95111314A patent/EP0679645A1/de not_active Withdrawn
- 1991-05-31 DE DE69121317T patent/DE69121317T2/de not_active Expired - Fee Related
- 1991-05-31 PL PL91305331A patent/PL170373B1/pl unknown
- 1991-05-31 NZ NZ248501A patent/NZ248501A/en unknown
- 1991-05-31 IE IE186191A patent/IE911861A1/en unknown
- 1991-05-31 NZ NZ238360A patent/NZ238360A/en unknown
- 1991-05-31 TW TW080104285A patent/TW224460B/zh active
- 1991-05-31 IL IL113599A patent/IL113599A/xx not_active IP Right Cessation
- 1991-05-31 AT AT91304935T patent/ATE141263T1/de not_active IP Right Cessation
- 1991-05-31 PL PL91290496A patent/PL166656B1/pl unknown
- 1991-05-31 FI FI912623A patent/FI912623A/fi not_active Application Discontinuation
- 1991-05-31 IL IL9833091A patent/IL98330A/en active IP Right Grant
- 1991-05-31 RU SU914895583A patent/RU2091374C1/ru active
- 1991-05-31 AU AU78097/91A patent/AU652753B2/en not_active Ceased
- 1991-05-31 HU HU911826A patent/HUT58707A/hu unknown
- 1991-05-31 DK DK91304935.9T patent/DK0459819T3/da active
- 1991-05-31 ES ES91304935T patent/ES2093078T3/es not_active Expired - Lifetime
- 1991-05-31 NO NO912100A patent/NO180375C/no unknown
- 1991-05-31 SK SK1643-91A patent/SK278444B6/sk unknown
- 1991-05-31 EP EP91304935A patent/EP0459819B1/de not_active Expired - Lifetime
- 1991-05-31 JP JP3235334A patent/JPH06340634A/ja active Pending
-
1994
- 1994-07-13 AU AU67455/94A patent/AU680252B2/en not_active Expired - Fee Related
-
1995
- 1995-06-30 HU HU95P/P00669P patent/HU211649A9/hu unknown
-
1996
- 1996-10-03 GR GR960402585T patent/GR3021237T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9012316D0 (en) | Pharmacologically active cns compounds | |
FI89709B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara arylderivat | |
HUP9901113A1 (hu) | Herbicid hatású és növényi növekedést szabályozó hatású 2-amino-4-biciklo-amino-1,3,5-triazinok | |
HUT59562A (en) | Cys-carboxamide derivatives, process for producing them and herbicide compositions containing them | |
PH25859A (en) | Composition for treatment of ischemic disorder | |
IL86462A0 (en) | Alkanesulfonanilide derivatives,processes for preparation thereof and pharmaceutical composition comprising the same | |
ES8708136A1 (es) | Procedimiento para la obtencion de derivados de acido barbiturico | |
ZA882374B (en) | Biologically active compounds | |
EP0726269A4 (de) | Quinolincarbonsäurederivat une seine salze | |
ES8703861A1 (es) | Un procedimiento para preparar nuevas 1,2,4-tiadiazinas | |
HU9600597D0 (en) | 4-alkylthio-pyrimidin-5-yl acetic acid derivates and fungicidal compositions containing them as an active ingredient | |
NO954109L (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte 5-arylpyrimidiner | |
TH11828EX (th) | สารประกอบต่าง ๆ ที่เกี่ยวกับ cns ซึ่งออกฤทธิ์ทางเภสัชวิทยา | |
MY104630A (en) | 4(1h) ouinoline derivatives | |
DE3464053D1 (en) | Pyrazine compounds, their preparation and their use, compositions containing them and method of combating undesired plant growth |